Correction: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
作者信息
Gurgenci Taylan, Hardy Janet, Huggett Georgie, Foster Karyn, Pelecanos Anita, Greer Ristan, Philip Jennifer, Haywood Alison, Mendis Ruwani, Yates Patsy, Good Phillip
机构信息
Mater Research Institute, University of Queensland, Brisbane, Australia.
Department of Supportive and Palliative Care, Mater Health, Brisbane, Australia.
出版信息
Trials. 2024 May 30;25(1):350. doi: 10.1186/s13063-024-08195-6.
Abstract
摘要
相似文献
1
Correction: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.更正：药用大麻（MedCan 3）：一项评估THC/CBD（1:20）减轻癌症患者症状负担的随机、多中心、双盲、安慰剂对照试验——一项随机对照试验的研究方案。
Trials. 2024 May 30;25(1):350. doi: 10.1186/s13063-024-08195-6.
2
Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.药用大麻（MedCan 3）：一项随机、多中心、双盲、安慰剂对照试验，评估 THC/CBD（1:20）减轻癌症患者症状负担的疗效 - 一项随机对照试验的研究方案。
Trials. 2024 May 1;25(1):293. doi: 10.1186/s13063-024-08091-z.
3
Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).口服药用大麻素缓解晚期癌症患者姑息治疗中的症状负担：一项评估 1:1 比例的 delta-9-四氢大麻酚（THC）和大麻二酚（CBD）疗效和安全性的双盲、安慰剂对照、随机临床试验。
Trials. 2020 Jul 6;21(1):611. doi: 10.1186/s13063-020-04541-6.
4
Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.口服 THC:CBD 大麻素提取物治疗难治性化疗引起的恶心和呕吐：一项随机、安慰剂对照、Ⅱ期交叉试验。
Ann Oncol. 2020 Nov;31(11):1553-1560. doi: 10.1016/j.annonc.2020.07.020. Epub 2020 Aug 13.
5
Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.基于大麻的药物——GW制药公司：高CBD、高THC、药用大麻——GW制药公司，THC与CBD比例
Drugs R D. 2003;4(5):306-9. doi: 10.2165/00126839-200304050-00005.
6
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).富含大麻素的 THC/CBD 口腔 cannabis 提取物用于预防化疗引起的恶心和呕吐的二级预防：一项先导和确证随机双盲安慰剂对照试验（CannabisCINV）的研究方案。
BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.
7
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.大麻素 CBD 是否使大麻更安全？四种不同 CBD：THC 比例的大麻的随机、双盲、交叉试验。
Neuropsychopharmacology. 2023 May;48(6):869-876. doi: 10.1038/s41386-022-01478-z. Epub 2022 Nov 16.
8
A randomised controlled trial of vaporised Δ-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.一项随机对照试验研究了在频繁和不频繁使用大麻的人群中单独使用和联合使用蒸气化 Δ-四氢大麻酚和大麻二酚的效果：急性中毒效应。
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2. Epub 2019 Jan 19.
9
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.δ-9-四氢大麻酚、大麻二酚及其组合对面部表情识别的急性影响：一项针对大麻使用者的随机、双盲、安慰剂对照研究。
Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5.
10
Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.基于模型的分析：联合给予大麻素后经控制蒸发给药的系统生物利用度。
Intern Med J. 2020 Jul;50(7):846-853. doi: 10.1111/imj.14415.
引用本文的文献
1
Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials.大麻素作为治疗神经性疼痛的天然替代方法：随机安慰剂对照试验的系统评价
Cureus. 2024 Sep 23;16(9):e70021. doi: 10.7759/cureus.70021. eCollection 2024 Sep.
本文引用的文献
1
Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.药用大麻（MedCan 3）：一项随机、多中心、双盲、安慰剂对照试验，评估 THC/CBD（1:20）减轻癌症患者症状负担的疗效 - 一项随机对照试验的研究方案。
Trials. 2024 May 1;25(1):293. doi: 10.1186/s13063-024-08091-z.
Zotero 插件